Abstract 1510TiP
Background
Osimertinib (Osi) is the standard first-line therapy for patients (pts) with advanced NSCLC harbouring common Epidermal Growth Factor Receptor (EGFR) mutations. Not all pts achieve durable benefit during treatment developing early resistance. Increasing evidence suggest a potential implication of Tumor Protein 53 (TP53) in the biological mechanisms underlying resistance to Tyrosine Kinase Inhibitors (TKIs). Our previous study on EGFR+ advanced NSCLC pts receiving first-line gefitinib showed that additional coexisting mutations (ACM) significantly decrease the efficacy of TKIs and, among them, TP53 mutations were exclusively documented in poor/intermediate responders than in good, supporting the potential role of this gene in influencing the response to anti-EGFR agents. These data highlight the need of applying more informative and comprehensive techniques for molecular analysis and treatment monitoring to implement the prediction of the awaited TKIs efficacy, identify pts who will not benefit from TKIs and ideally build for them a rational polytherapy strategy.
Trial design
TEMPLE-2 (NCT05785208) is a prospective, biomarker-driven, multicenter, open-label, clinical trial to evaluate the efficacy of Osi in treatment-nai¨ve patients affected by EGFR+ NSCLC according to TP53 mutational status. Inclusion criteria are: age >18 years, histologically confirmed diagnosis of EGFR+ NSCLC, available tumor tissue sample. The study consists of a screening phase to assess eligibility; a treatment phase in which pts will receive Osi at standard dose of 80 mg daily and a follow-up phase to monitor survival status and subsequent therapies. A population of 122 enrolled pts is expected, 61 TP51-wilde type and 61 TP-53 mutant. Primary endpoint is Progression Free Survival (PFS) according to TP53 mutational status; key secondary endpoints are Overall Survival (OS), Overall Response Rate (ORR), Disease Control Rate (DCR), Time to Central Nervous System (CNS) Progression, CNS ORR and Safety. Concomitant genomic alterations will be evaluated in tissue and blood at baseline and progression; ctDNA will be monitored during treatment. Enrollment is ongoing.
Clinical trial identification
NCT05785208.
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario Agostino Gemelli IRCCS.
Funding
AstraZeneca.
Disclosure
E. Bria: Financial Interests, Personal, Advisory Board: AZ, Roche, BMS, MSD, Eli Lilly, Amgen, Pfizer, Novartis; Financial Interests, Personal, Invited Speaker: AZ, Roche, BMS, MSD, Eli Lilly, Pfizer, Novartis; Financial Interests, Institutional, Research Grant: AZ, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1523P - Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Presenter: Mustapha Tehfe
Session: Poster session 21
1524P - First-line TST001 plus capecitabine and oxaliplatin (CAPOX) for advanced G/GEJ cancer with CLDN18.2 positive overall survival data from study transtar102-Cohort C
Presenter: Lin Shen
Session: Poster session 21
1526P - Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1
Presenter: Zev Wainberg
Session: Poster session 21
1527P - Efficacy and safety of infigratinib in locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma patients with FGFR2 gene amplification
Presenter: Jiajia Yuan
Session: Poster session 21
1528P - A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors
Presenter: Daniel Olson
Session: Poster session 21
1529P - Tislelizumab plus chemotherapy sequential neo-chemoradiotherapy therapy as total neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma (ETNT)
Presenter: Wenwu He
Session: Poster session 21
1530P - Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW
Presenter: Florian Lordick
Session: Poster session 21
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21